Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Latent diabetes warrants earlier, tighter glycemic control

Publish date:: March 3, 2020

Key clinical point: Increasing microvascular risks in adults with latent autoimmune diabetes warrant earlier screening and tighter glycemic control.

Major finding: Risk for microvascular complications in latent autoimmune diabetes of adulthood exceeds that in type 2 diabetes by 25% after 9 years.

Study details: Post hoc analysis of 5,028 patients in the United Kingdom Prospective Diabetes Study follow-up cohort.

Disclosures: Dr. Maddaloni disclosed financial relationships with Sanofi, Eli Lilly, Abbott and AstraZeneca. A coauthor disclosed financial relationships with Boehringer Ingelheim, Merck, AstraZeneca, Bayer, Novartis, and Novo Nordisk. All other authors disclosed no financial relationships. The study received funding from the European Foundation for the Study of Diabetes Mentorship Program supported by AstraZeneca.

Citation:

Maddaloni E et al. Lancet Diabetes Endocrinol. 2020 Feb 4. doi: 10.1016/S2213-8587(20)30003-6.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,